Sarepta Therapeutics presented topline results from Part 2 of Study SRP-9001-102 (Study 102), an ongoing phase 2 study evaluating a single dose of investigational gene…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.